Patent · US Active

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

US10222377B2 · kind B2 · utility

0Cited by

1References

61Claims

0Family size

Assignees

Basilea Pharmaceutica AG · CH
RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

Heidi Lane · Biel-Benken, CH
Felix Bachmann · Basel, CH
Madlaina Breuleux · Basel, CH
Michael Boutros · Heidelberg, DE
Daniel Gilbert · Koblenzer Straße, DE
Xian Zhang · Beijing, CN

Key dates

Filing date	Jan 19, 2012
Grant date	Mar 5, 2019
Priority date	—
Expiry date	Jan 25, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.